emirates7 - Scientists at Tomsk Polytechnic University (TPU) have developed and patented Russia’s first theranostic pair—innovative radiopharmaceuticals designed for both diagnosing and treating prostate cancer. According to TPU’s press service, the initial stage of pilot clinical trials has yielded successful results.
The researchers at Tomsk are leading the way in Russian theranostics, a cutting-edge medical approach that integrates diagnosis and therapy for cancer treatment. Until now, only two theranostic molecules existed globally for treating neuroendocrine tumors and prostate cancer, both developed by foreign companies. This project marks the first such achievement in Russia.
Roman Zelchan, the project’s lead scientist and senior researcher at the Oncoteranostics Research Centre within TPU’s Research School of Chemical and Biomedical Technologies, stated, “It is now safe to say that Tomsk Polytechnic University has created the first domestically developed theranostic pair.” Zelchan is also a senior research associate at the Department of Radionuclide Therapy and Diagnostics at the Tomsk Research Institute of Oncology, which operates under the Tomsk Medical Research Centre.
The novel radiopharmaceuticals are derived from the BQ–PSMA compound, enabling the creation of both diagnostic and therapeutic agents. When combined with the diagnostic radioactive isotope technetium-99m, the compound functions as a "signal beacon," highlighting tumor cells. The addition of the therapeutic isotope lutetium-177 further enhances its effectiveness in targeting and treating cancerous cells.
Prostate cancer is the second most frequently diagnosed cancer worldwide, affecting approximately one in eight men over their lifetime.
The researchers at Tomsk are leading the way in Russian theranostics, a cutting-edge medical approach that integrates diagnosis and therapy for cancer treatment. Until now, only two theranostic molecules existed globally for treating neuroendocrine tumors and prostate cancer, both developed by foreign companies. This project marks the first such achievement in Russia.
Roman Zelchan, the project’s lead scientist and senior researcher at the Oncoteranostics Research Centre within TPU’s Research School of Chemical and Biomedical Technologies, stated, “It is now safe to say that Tomsk Polytechnic University has created the first domestically developed theranostic pair.” Zelchan is also a senior research associate at the Department of Radionuclide Therapy and Diagnostics at the Tomsk Research Institute of Oncology, which operates under the Tomsk Medical Research Centre.
The novel radiopharmaceuticals are derived from the BQ–PSMA compound, enabling the creation of both diagnostic and therapeutic agents. When combined with the diagnostic radioactive isotope technetium-99m, the compound functions as a "signal beacon," highlighting tumor cells. The addition of the therapeutic isotope lutetium-177 further enhances its effectiveness in targeting and treating cancerous cells.
Prostate cancer is the second most frequently diagnosed cancer worldwide, affecting approximately one in eight men over their lifetime.